A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-61820-z
Affiliations:
32
Authors:
61
Go to article
Institutions Authors Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
13.250000
13.250000
 0.22
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, United States of America (USA)
9.700000
 0.16
Harvard Medical School (HMS), United States of America (USA)
6.533333
 0.11
Broad Institute of MIT and Harvard, United States of America (USA)
4.616667
 0.08
Foundation Medicine, Inc., United States of America (USA)
3.333333
 0.05
Queen Mary University of London (QMUL), United Kingdom (UK)
3.000000
 0.05
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada
2.000000
 0.03
McGill University, Canada
2.000000
 0.03
Arnold Palmer Hospital for Children, United States of America (USA)
2.000000
 0.03
Brain and Spine Institute (ICM), France
2.000000
 0.03
CHU de Québec, UL, Canada
2.000000
 0.03
Hopp Children's Cancer Center Heidelberg (KiTZ), Germany
1.866667
 0.03
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany
1.733333
 0.03
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany
1.533333
 0.03
National Center for Tumor Diseases (NCT) Heidelberg, Germany
1.283333
 0.02
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
 0.02
Brigham and Women's Hospital (BWH), United States of America (USA)
0.750000
 0.01
Boston Children's Hospital (BCH), United States of America (USA)
0.750000
 0.01
German Consortium of Translational Cancer Research (DKTK), Germany
0.583333
 0.01
LabCorp, United States of America (USA)
0.333333
 0.01
Atrium Health Wake Forest, United States of America (USA)
0.333333
 0.01
Uppsala University (UU), Sweden
0.200000
 0.00
Uppsala University Hospital, Sweden
0.200000
 0.00
Interested in Oncology and Carcinogenesis?